title: Bupropion-induced erythema multiforme.
abstract: The high rate of dermatologic adverse effects associated with bupropion use may extend to its sustained-release preparation, currently prescribed extensively for smoking cessation as well as for treatment of depressive conditions. We report what we believe to be the first case, in a 31-year-old woman, of erythema multiforme after administration of sustained-release bupropion (Wellbutrin SR) for treatment of depression. This report emphasizes that prescribers must aggressively follow up their patients who have rashes or urticaria, discontinuing the medication as soon as erythema multiforme is suspected and watching closely for the emergence of potentially life-threatening dermatologic conditions.
authors.affiliation: Department of Psychiatry, Ramstein Air Base, Germany.
authors.forename: T W
authors.initials: TW
authors.lastname: Lineberry
authors.forename: G E
authors.initials: GE
authors.lastname: Peters
authors.forename: J M
authors.initials: JM
authors.lastname: Bostwick
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000359:Aftercare; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D016642:Bupropion / Q000009:adverse effects*; D003692:Delayed-Action Preparations; D003866:Depressive Disorder / Q000188:drug therapy*; D018450:Disease Progression; D016903:Drug Monitoring; D004892:Erythema Multiforme / Q000139:chemically induced* / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D006801:Humans; D011241:Prednisone / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D018687:Antidepressive Agents, Second-Generation; D003692:Delayed-Action Preparations; D016642:Bupropion; D011241:Prednisone